Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2014, Article ID 626319, 10 pages
http://dx.doi.org/10.1155/2014/626319
Research Article

Peroxisome Proliferator Activator Receptor (PPAR)-γ Ligand, but Not PPAR-α, Ameliorates Cyclophosphamide-Induced Oxidative Stress and Inflammation in Rat Liver

1Department of Pharmacology, Faculty of Medicine, Minia University, Minia 61511, Egypt
2Department of Histology, Faculty of Medicine, Minia University, Minia 61511, Egypt

Received 31 August 2013; Revised 9 March 2014; Accepted 10 March 2014; Published 2 April 2014

Academic Editor: Howard P. Glauert

Copyright © 2014 Azza A. K. El-Sheikh and Rehab A. Rifaai. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Emadi, R. J. Jones, and R. A. Brodsky, “Cyclophosphamide and cancer: golden anniversary,” Nature Reviews Clinical Oncology, vol. 6, no. 11, pp. 638–647, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Haubitz, “Acute and long-term toxicity of cyclophosphamide,” Transplantationsmedizin, vol. 19, supplement 2, pp. S26–S31, 2007. View at Google Scholar · View at Scopus
  3. A. H. Viswanatha Swamy, U. M. Patel, B. C. Koti, P. C. Gadad, N. L. Patel, and A. H. Thippeswamy, “Cardioprotective effect of Saraca indica against cyclophosphamide induced cardiotoxicity in rats: a biochemical, electrocardiographic and histopathological study,” Indian Journal of Pharmacology, vol. 45, no. 1, pp. 44–48, 2013. View at Google Scholar
  4. W. Kim, S. H. Kim, S. K. Park, and M. S. Chang, “Astragalus membranaceus ameliorates reproductive toxicity induced by cyclophosphamide in male mice,” Phytotherapy Research, vol. 26, no. 9, pp. 1418–1421, 2012. View at Google Scholar
  5. N. E. Aikawa, A. M. Sallum, R. M. Pereira et al., “Subclinical impairment of ovarian reserve in juvenile systemic lupus erythematosus after cyclophosphamide therapy,” Clinical and Experimental Rheumatology, vol. 30, no. 3, pp. 445–449, 2012. View at Google Scholar
  6. J. W. Goldberg and M. D. Lidsky, “Cyclophosphamide-associated hepatotoxicity,” Southern Medical Journal, vol. 78, no. 2, pp. 222–223, 1985. View at Google Scholar · View at Scopus
  7. M. E. de Jonge, A. D. R. Huitema, J. H. Beijnen, and S. Rodenhuis, “High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy,” British Journal of Cancer, vol. 94, no. 9, pp. 1226–1230, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. H. Akay, T. Akay, S. Secilmis, Z. Kocak, and Ö. Donderici, “Hepatotoxicity after low-dose cyclophosphamide therapy,” Southern Medical Journal, vol. 99, no. 12, pp. 1399–1400, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Martínez-Gabarrón, R. Enríquez, A. E. Sirvent, M. García-Sepulcre, I. Millán, and F. Amorós, “Hepatotoxity after cyclophosphamide treatment in a patient with MPO-ANCA vasculitis,” Nefrologia, vol. 31, no. 4, pp. 496–498, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. A. K. Souid, K. A. Tacka, K. A. Galvan, and H. S. Penefsky, “Immediate effects of anticancer drugs on mitochondrial oxygen consumption,” Biochemical Pharmacology, vol. 66, no. 6, pp. 977–987, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Zarei and T. Shivanandappa, “Amelioration of cyclophosphamide-induced hepatotoxicity by the root extract of Decalepis hamiltonii in mice,” Food and Chemical Toxicology, vol. 57, pp. 179–184, 2013. View at Google Scholar
  12. T. P. Hamsa and G. Kuttan, “Ipomoea obscura ameliorates cyclophosphamide induced toxicity by modulating the immune system and levels of proinflammatory cytokine and GSH,” Canadian Journal of Physiology and Pharmacology, vol. 88, no. 11, pp. 1042–1053, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. K. McKeage, G. M. Keating, D. Bhatnagar, M. B. Elam, M. Farnier, and S. M. Mohiuddin, “Fenofibrate: a review of its use in dyslipidaemia,” Drugs, vol. 71, no. 14, pp. 1917–1946, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. P. de Pablos-Velasco, “Pioglitazone: beyond glucose control,” Expert Review of Cardiovascular Therapy, vol. 8, no. 8, pp. 1057–1067, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Ibrahim, A. El-Sheikh, H. Khalaf, and A. Abdelrahman, “Protective effect of peroxisome proliferator activator receptor (PPAR)-α and -γ ligands against methotrexate-induced nephrotoxicity,” Immunopharmacology and Immunotoxicology, 2014. View at Publisher · View at Google Scholar
  16. X. Shi, D. Yao, B. A. Gosnell, and C. Chen, “Lipidomic profiling reveals protective function of fatty acid oxidation in cocaine-induced hepatotoxicity,” Journal of Lipid Research, vol. 53, no. 11, pp. 2318–2330, 2012. View at Google Scholar
  17. S. Y. Pan, Q. Yu, Y. Zhang et al., “Dietary Fructus Schisandrae extracts and fenofibrate regulate the serum/hepatic lipid-profile in normal and hypercholesterolemic mice, with attention to hepatotoxicity,” Lipids in Health and Disease, vol. 11, article 120, 2012. View at Publisher · View at Google Scholar
  18. D. Hajdu, K. Aiglová, I. Vinklerová, and K. Urbánek, “Acute cholestatic hepatitis induced by fenofibrate,” Journal of Clinical Pharmacy and Therapeutics, vol. 34, no. 5, pp. 599–602, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. K. G. Tolman, J. W. Freston, S. Kupfer, and P. Alfonso, “Liver safety in patients with type 2 diabetes treated with pioglitazone: Results from a 3-year, randomized, comparator-controlled study in the US,” Drug Safety, vol. 32, no. 9, pp. 787–800, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. J. S. Floyd, E. Barbehenn, P. Lurie, and S. M. Wolfe, “Case series of liver failure associated with rosiglitazone and pioglitazone,” Pharmacoepidemiology and Drug Safety, vol. 18, no. 12, pp. 1238–1243, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. A. D. Patterson, Y. M. Shah, T. Matsubara, K. W. Krausz, and F. J. Gonzalez, “Peroxisome proliferator-activated receptor alpha induction of uncoupling protein 2 protects against acetaminophen-induced liver toxicity,” Hepatology, vol. 56, no. 1, pp. 281–290, 2012. View at Google Scholar
  22. T. Karakan, M. Kerem, M. Cindoruk, D. Engin, M. Alper, and O. Akin, “PPAR-alpha agonist treatment increases trefoil factor family-3 expression and attenuates apoptosis in the liver tissue of bile duct-ligated rats,” The Turkish Journal of Gastroenterology, vol. 24, no. 2, pp. 134–140, 2013. View at Google Scholar
  23. M. H. Somi, B. Hajipour, N. A. Asl et al., “Pioglitazone attenuates ischemia/reperfusion-induced liver injury in rats,” Transplantation Proceedings, vol. 41, no. 10, pp. 4105–4109, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. J. S. Zhao, F. S. Zhu, S. Liu, C. Q. Yang, and X. M. Chen, “Pioglitazone ameliorates nonalcoholic steatohepatitis by down-regulating hepatic nuclear factor-kappa B and cyclooxygenases-2 expression in rats,” Chinese Medical Journal, vol. 125, no. 13, pp. 2316–2321, 2012. View at Google Scholar
  25. M. Olukman, E. D. Sezer, S. Ülker, E. Y. Szmen, and G. M. Çnar, “Fenofibrate treatment enhances antioxidant status and attenuates endothelial dysfunction in streptozotocin-induced diabetic rats,” Experimental Diabetes Research, vol. 2010, Article ID 828531, 10 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Jnaneshwari, M. Hemshekhar, M. S. Santhosh et al., “Crocin, a dietary colorant mitigates cyclophosphamide-induced organ toxicity by modulating antioxidant status and inflammatory cytokines,” The Journal of Pharmacy and Pharmacology, vol. 65, no. 4, pp. 604–614, 2013. View at Google Scholar
  27. J. D. Bancroft and M. Gamble, Theory and Practice of Histological Techniques, Churchill Livingstone, New York, NY, USA, 5th edition, 2008.
  28. M. Ozsoy, Y. Ozsoy, T. Coskun, K. Naml, A. Var, and B. Özyurt, “The effects of l-arginine on liver damage in experimental acute cholestasis an immunohistochemical study,” HPB Surgery, vol. 2011, Article ID 306069, 5 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. K. V. Sastry, R. P. Moudgal, J. Mohan, J. S. Tyagi, and G. S. Rao, “Spectrophotometric determination of serum nitrite and nitrate by copper-cadmium alloy,” Analytical Biochemistry, vol. 306, no. 1, pp. 79–82, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. J. A. Buege and S. D. Aust, “Microsomal lipid peroxidation,” Methods in Enzymology, vol. 52, pp. 302–310, 1978. View at Publisher · View at Google Scholar · View at Scopus
  31. E. Selvakumar, C. Prahalathan, Y. Mythili, and P. Varalakshmi, “Mitigation of oxidative stress in cyclophosphamide-challenged hepatic tissue by DL-α-lipoic acid,” Molecular and Cellular Biochemistry, vol. 272, no. 1-2, pp. 179–185, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. S. S. Dadarkar, L. C. Fonseca, P. B. Mishra et al., “Phenotypic and genotypic assessment of concomitant drug-induced toxic effects in liver, kidney and blood,” Journal of Applied Toxicology, vol. 31, no. 2, pp. 117–130, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. E. L. Lushnikova, O. P. Molodykh, L. M. Nepomnyashchikh, A. A. Bakulina, and Y. A. Sorokina, “Ultrastructurural picture of cyclophosphamide-induced damage to the liver,” Bulletin of Experimental Biology and Medicine, vol. 151, no. 6, pp. 751–756, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Lazo, E. Selvin, and J. M. Clark, “Brief communication: clinical implications of short-term variability in liver function test results,” Annals of Internal Medicine, vol. 148, no. 5, pp. 348–352, 2008. View at Google Scholar · View at Scopus
  35. D. H. Vroon and Z. Israili, “Aminotransferases,” in Clinical Methods: The History, Physical, and Laboratory Examinations, H. K. Walker, W. D. Hall, and J. W. Hurst, Eds., chapter 99, Butterworths, Boston, Mass, USA, 3rd edition, 1990. View at Google Scholar
  36. N. J. Fernandez and B. A. Kidney, “Alkaline phosphatase: beyond the liver,” Veterinary Clinical Pathology, vol. 36, no. 3, pp. 223–233, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. K. Kotoh, M. Enjoji, M. Kato, M. Kohjima, M. Nakamuta, and R. Takayanagi, “A new parameter using serum lactate dehydrogenase and alanine aminotransferase level is useful for predicting the prognosis of patients at an early stage of acute liver injury: A retrospective study,” Comparative Hepatology, vol. 7, article 6, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. Y. Mano, H. Tsukada, T. Kurihara, M. Nomura, K. Yokogawa, and K.-I. Miyamoto, “Development of dosage design of hepatic metabolizing drugs using serum albumin level in chronic hepatic failure,” Biological and Pharmaceutical Bulletin, vol. 29, no. 8, pp. 1692–1699, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. K. Jyothi, A. G. Reddy, K. S. Gopi, B. A. Kumar, and G. D. Reddy, “A study on free radical-induced renal toxicity due to cyclophosphamide and its amelioration with N-acetyl cysteine,” Toxicology International, vol. 16, no. 2, pp. 137–139, 2009. View at Google Scholar
  40. F. Liu, X. L. Li, T. Lin et al., “The cyclophosphamide metabolite, acrolein, induces cytoskeletal changes and oxidative stress in Sertoli cells,” Molecular Biology Reports, vol. 39, no. 1, pp. 493–500, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. C. C. Wang, T. I. Weng, E. T. Wu, M. H. Wu, R. S. Yang, and S. H. Liu SH, “Involvement of interleukin-6-regulated nitric oxide synthase in hemorrhagic cystitis and impaired bladder contractions in young rats induced by acrolein, a urinary metabolite of cyclophosphamide,” Toxicological Sciences, vol. 131, no. 1, pp. 302–310, 2013. View at Google Scholar
  42. P. Abraham and E. Sugumar, “Increased glutathione levels and activity of PON1 (phenyl acetate esterase) in the liver of rats after a single dose of cyclophosphamide: a defense mechanism?” Experimental and Toxicologic Pathology, vol. 59, no. 5, pp. 301–306, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Taye and A. A. El-Sheikh, “Lectin-like oxidized low-density lipoprotein receptor 1 pathways,” European Journal of Clinical Investigation, vol. 43, no. 7, pp. 740–745, 2013. View at Google Scholar
  44. T. Moustafa, P. Fickert, C. Magnes et al., “Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury,” Gastroenterology, vol. 142, no. 1, pp. 140–151, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. K. Dohmen, C. Y. Wen, S. Nagaoka et al., “Fenofibrate-induced liver injury,” World Journal of Gastroenterology, vol. 11, no. 48, pp. 7702–7703, 2005. View at Google Scholar · View at Scopus
  46. A. Rodríguez-Vilarrupla, B. Laviña, H. García-Calderó et al., “PPARalpha activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats,” Journal of Hepatology, vol. 56, no. 5, pp. 1033–1039, 2012. View at Google Scholar
  47. V. Boshra and A. M. Moustafa, “Effect of preischemic treatment with fenofibrate, a peroxisome proliferator-activated receptor-α ligand, on hepatic ischemia-reperfusion injury in rats,” Journal of Molecular Histology, vol. 42, no. 2, pp. 113–122, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Makowka, P. Dryja, G. Chwatko, E. Bald, and M. Nowicki, “Treatment of chronic hemodialysis patients with low-dose fenofibrate effectively reduces plasma lipids and affects plasma redox status,” Lipids in Health and Disease, vol. 11, article 47, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. A. Kobayashi, Y. Suzuki, H. Kuno, S. Sugai, H. Sakakibara, and K. Shimoi, “Effects of fenofibrate on plasma and hepatic transaminase activities and hepatic transaminase gene expression in rats,” Journal of Toxicological Sciences, vol. 34, no. 4, pp. 377–387, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Broncel, D. Cieślak, M. Koter-Michalak, P. Duchnowicz, K. Mackiewicz, and J. Chojnowska-Jezierska, “The anti-inflammatory and antioxidants effects of micronized fenofibrate in patients with visceral obesity and dyslipidemia,” Polski Merkuriusz Lekarski, vol. 20, no. 119, pp. 547–550, 2006. View at Google Scholar · View at Scopus
  51. J. Kowalski, J. Olejniczak, J. Błaszczyk et al., “Effect of fluvastatin and fenofibrate on the antioxidative barrier enzyme activity in patients with dyslipidemia,” Polski Merkuriusz Lekarski, vol. 14, no. 82, pp. 285–288, 2003. View at Google Scholar · View at Scopus
  52. J. Kowalski, J. Błaszczyk, J. Olejniczak et al., “Effect of fluvastatin and fenofibrate on reactive oxygen species generation and lipid peroxidation in patients with dyslipidaemia,” Polski Merkuriusz Lekarski, vol. 14, no. 82, pp. 279–284, 2003. View at Google Scholar · View at Scopus
  53. J. Nishimura, Y. Dewa, T. Okamura et al., “Possible involvement of oxidative stress in fenofibrate-induced hepatocarcinogenesis in rats,” Archives of Toxicology, vol. 82, no. 9, pp. 641–654, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. A. Zambon, P. Gervois, P. Pauletto, J. C. Fruchart, and B. Staels, “Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-α activators: clinical and experimental evidence,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 5, pp. 977–986, 2006. View at Publisher · View at Google Scholar · View at Scopus
  55. A. Bedir, Y. Aliyazicioglu, B. Bilgici et al., “Assessment of genotoxicity in rats treated with the antidiabetic agent, pioglitazone,” Environmental and Molecular Mutagenesis, vol. 49, no. 3, pp. 185–191, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. P. J. Hsiao, T. J. Hsieh, K. K. Kuo et al., “Pioglitazone retrieves hepatic antioxidant DNA repair in a mice model of high fat diet,” BMC Molecular Biology, vol. 9, article 82, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. A. Gumieniczek, “Effect of the new thiazolidinedione-pioglitazone on the development of oxidative stress in liver and kidney of diabetic rabbits,” Life Sciences, vol. 74, no. 5, pp. 553–562, 2003. View at Publisher · View at Google Scholar · View at Scopus
  58. N. Enomoto, Y. Takei, S. Yamashima, K. Ikejima, T. Kitamura, and N. Sato, “Protective effect of pioglitazone against endotoxin-induced liver injury through prevention of Kupffer cell sensitization,” Alcoholism: Clinical and Experimental Research, vol. 29, supplement 3, pp. 216S–219S, 2005. View at Publisher · View at Google Scholar · View at Scopus
  59. M. Razavizade, R. Jamali, A. Arj, S. M. Matini, A. Moraveji, and E. Taherkhani, “The effect of pioglitazone and metformin on liver function tests, insulin resistance, and liver fat content in nonalcoholic Fatty liver disease: a randomized double blinded clinical trial,” Hepatitis Monthly, vol. 13, no. 5, article e9270, 2013. View at Google Scholar
  60. P. Shokouh, A. Joharimoghadam, H. Roohafza et al., “Effects of pioglitazone on asymmetric dimethylarginine and components of the metabolic syndrome in nondiabetic patients (EPICAMP study): a double-blind, randomized clinical trial,” PPAR Research, vol. 2013, Article ID 358074, 9 pages, 2013. View at Publisher · View at Google Scholar
  61. Y. Wang, Q. W. Lin, P. P. Zheng, J. S. Zhang, and F. R. Huang, “DHA inhibits protein degradation more efficiently than EPA by regulating the PPARgamma/NFkappaB pathway in C2C12 myotubes,” BioMed Research International, vol. 2013, Article ID 318981, 2013. View at Publisher · View at Google Scholar
  62. T. Chen, X. Jin, B. H. Crawford et al., “Cardioprotection from oxidative stress in the newborn heart by activation of PPARgamma is mediated by catalase,” Free Radical Biology and Medicine, vol. 53, no. 2, pp. 208–215, 2012. View at Google Scholar
  63. C. Zou, H. Hu, X. Xi, Z. Shi, G. Wang, and X. Huang, “Pioglitazone protects against renal ischemia-reperfusion injury by enhancing antioxidant capacity,” The Journal of Surgical Research, vol. 184, no. 2, pp. 1092–1095, 2013. View at Google Scholar
  64. A. Gumieniczek, H. Hopkała, and A. Z̧bek, “Protective effects of a PPARγ agonist pioglitazone on anti-oxidative system in testis of diabetic rabbits,” Pharmazie, vol. 63, no. 5, pp. 377–378, 2008. View at Publisher · View at Google Scholar · View at Scopus